Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients

被引：28

作者：

Chalhoub, Hussein ^{[1
]}

Tunney, Michael ^{[2
]}

Elborn, J. Stuart ^{[2
]}

Vergison, Anne ^{[3
]}

Denis, Olivier ^{[4
]}

Plesiat, Patrick ^{[5
]}

Kahl, Barbara C. ^{[6
]}

Van Bambeke, Francoise ^{[1
]}

Tulkens, Paul M. ^{[1
]}

机构：

[1] Catholic Univ Louvain, Louvain Drug Res Inst, Pharmacol Cellulaire & Mol, B-1200 Brussels, Belgium

[2] Queens Univ Belfast, CF & Airways Microbiol Res Grp, Belfast, Antrim, North Ireland

[3] Hop Univ Enfants Reine Fabiola, Unite Malad Infect, Brussels, Belgium

[4] Free Univ Brussels, Hop Erasme, Lab Microbiol, B-1070 Brussels, Belgium

[5] Hop Jean Minjoz, Lab Bacteriol, F-25030 Besancon, France

[6] Univ Hosp Munster, Med Microbiol, Munster, Germany

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2015年 / 70卷 / 05期

关键词：

carbapenemases; extended-spectrum beta-lactamases; ESBLs; beta-lactamase inhibition; P; aeruginosa; IN-VITRO ACTIVITY; EXACERBATIONS;

D O I：

10.1093/jac/dku551

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：1596 / 1598

页数：4

共 9 条

[1]

[Anonymous], CYST FIBR FDN PAT RE

[2] Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis [J].

Conway, SP ;

Pond, HN ;

Watson, A ;

Etherington, C ;

Robey, HL ;

Goldman, MH .

THORAX, 1997, 52 (11) :987-993

[3] Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases [J].

Ehmann, David E. ;

Jahic, Haris ;

Ross, Philip L. ;

Gu, Rong-Fang ;

Hu, Jun ;

Durand-Reville, Thomas F. ;

Lahiri, Sushmita ;

Thresher, Jason ;

Livchak, Stephania ;

Gao, Ning ;

Palmer, Tiffany ;

Walkup, Grant K. ;

Fisher, Stewart L. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (39) :27960-27971

[4] Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value [J].

Flamm, Robert K. ;

Stone, Gregory G. ;

Sader, Helio S. ;

Jones, Ronald N. ;

Nichols, Wright W. .

JOURNAL OF CHEMOTHERAPY, 2014, 26 (06) :333-338

[5] Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review [J].

Gaspar, M. C. ;

Couet, W. ;

Olivier, J. -C. ;

Pais, A. A. C. C. ;

Sousa, J. J. S. .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2013, 32 (10) :1231-1252

[6] Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study [J].

Llanes, Catherine ;

Pourcel, Christine ;

Richardot, Charlotte ;

Plesiat, Patrick ;

Fichant, Gwennaele ;

Cavallo, Jean-Didier ;

Merens, Audrey .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (08) :1763-1771

[7] In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters [J].

Mushtaq, Shazad ;

Warner, Marina ;

Livermore, David M. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (11) :2376-2381

[8] In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study) [J].

Walkty, A. ;

DeCorby, M. ;

Lagace-Wiens, P. R. S. ;

Karlowsky, J. A. ;

Hoban, D. J. ;

Zhanel, G. G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (06) :2992-2994

[9] Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: V. Aminoglycosides [J].

Young, David C. ;

Zobell, Jeffery T. ;

Stockmann, Chris ;

Waters, C. Dustin ;

Ampofo, Krow ;

Sherwin, Catherine M. T. ;

Spigarelli, Michael G. .

PEDIATRIC PULMONOLOGY, 2013, 48 (11) :1047-1061

← 1 →